136 related articles for article (PubMed ID: 38406077)
1. ST-Segment Elevation Myocardial Infarction Caused by 5-Fluorouracil-Related Cardiotoxicity.
Balaji N; Dixit P; Adams AM; Faiz F; Ngwainmbi D; Henry G; Ghasemzadeh N
Cureus; 2024 Jan; 16(1):e52864. PubMed ID: 38406077
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine-induced coronary artery vasospasm in a patient who previously experienced a similar episode with fluorouracil therapy.
Karakulak UN; Aladağ E; Maharjan N; Övünç K
Turk Kardiyol Dern Ars; 2016 Jan; 44(1):71-4. PubMed ID: 26875134
[TBL] [Abstract][Full Text] [Related]
3. 5-Fluorouracil-related Cardiotoxicity with Coronary Vasospasms.
Faheem B; Kania B; Ashkar H; Bondili L; Maroules M
J Community Hosp Intern Med Perspect; 2022; 12(5):71-74. PubMed ID: 36262502
[TBL] [Abstract][Full Text] [Related]
4. What the Cardiologist Needs to Consider in the Management of Oncologic Patients with STEMI-Like Syndrome: A Case Report and Literature Review.
Aleksova A; Gagno G; Pierri A; Todaro C; Fluca AL; Orlando V; Guglielmi A; Beltrami AP; Sinagra G
Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34204714
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and Management of a Patient With 5-Fluorouracil-Induced ST Elevation and Nonsustained Ventricular Tachycardia as a Late Presentation of Cardiotoxicity and Successful 5-Fluorouracil Rechallenge.
Medepalli LC; Mahmood TS; Liberman H; Medepalli AM; Bagwell TW
Cureus; 2022 Oct; 14(10):e30489. PubMed ID: 36415417
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer.
Dyhl-Polk A; Vaage-Nilsen M; Schou M; Vistisen KK; Lund CM; Kümler T; Appel JM; Nielsen DL
Acta Oncol; 2020 Apr; 59(4):475-483. PubMed ID: 31931649
[No Abstract] [Full Text] [Related]
8. Fluoropyrimidine-Associated Cardiotoxicity.
Kanduri J; More LA; Godishala A; Asnani A
Cardiol Clin; 2019 Nov; 37(4):399-405. PubMed ID: 31587781
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for remote ischemic conditioning in preventing 5-fluorouracil-induced coronary vasospasm?
Chong J; Ho AF; Yap J; Bulluck H; Hausenloy DJ
Cond Med; 2019 Oct; 2(5):204-212. PubMed ID: 32133437
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine-mediated heart failure in colorectal cancer: a case series.
McAndrew EN; Jassal DS; Goldenberg BA; Kim CA
Eur Heart J Case Rep; 2021 Mar; 5(3):ytab079. PubMed ID: 33709051
[TBL] [Abstract][Full Text] [Related]
11. 5-fluorouracil and cardiotoxicity: a review.
Sara JD; Kaur J; Khodadadi R; Rehman M; Lobo R; Chakrabarti S; Herrmann J; Lerman A; Grothey A
Ther Adv Med Oncol; 2018; 10():1758835918780140. PubMed ID: 29977352
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
Pu J; Ding S; Ge H; Han Y; Guo J; Lin R; Su X; Zhang H; Chen L; He B;
Circulation; 2017 Oct; 136(16):1462-1473. PubMed ID: 28844990
[TBL] [Abstract][Full Text] [Related]
13. Comparing the long-term outcomes in chronic coronary syndrome patients with prior ST-segment and non-ST-segment elevation myocardial infarction: findings from the TIGRIS registry.
Krishnamurthy SN; Pocock S; Kaul P; Owen R; Goodman SG; Granger CB; Nicolau JC; Simon T; Westermann D; Yasuda S; Andersson K; Brandrup-Wognsen G; Hunt PR; Brieger DB; Cohen MG
BMJ Open; 2023 Dec; 13(12):e070237. PubMed ID: 38110389
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity related to 5-fluorouracil chemotherapy: a report of two cases.
Weng MC; Wang WB; Chao TY
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Mar; 55(3):266-9. PubMed ID: 7780886
[TBL] [Abstract][Full Text] [Related]
15. Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm.
Shah NR; Shah A; Rather A
J Oncol Pharm Pract; 2012 Mar; 18(1):132-5. PubMed ID: 21321041
[TBL] [Abstract][Full Text] [Related]
16. API expert consensus document on management of ischemic heart disease.
Association of Physicians of India
J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
[TBL] [Abstract][Full Text] [Related]
17. In-hospital major adverse cardiovascular events after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: a retrospective study under the China chest pain center (standard center) treatment system.
Huang L; Zhang J; Huang Q; Cui R; Chen J
BMC Cardiovasc Disord; 2023 Apr; 23(1):198. PubMed ID: 37069503
[TBL] [Abstract][Full Text] [Related]
18. Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
Chakrabarti S; Sara J; Lobo R; Eiring R; Finnes H; Mitchell J; Hartgers M; Okano A; Halfdanarson T; Grothey A
Clin Colorectal Cancer; 2019 Mar; 18(1):52-57. PubMed ID: 30396850
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.
Peng J; Dong C; Wang C; Li W; Yu H; Zhang M; Zhao Q; Zhu B; Zhang J; Li W; Wang F; Wu Q; Zhou W; Yuan Y; Qiu M; Chen G
Cancer Commun (Lond); 2018 May; 38(1):22. PubMed ID: 29764506
[TBL] [Abstract][Full Text] [Related]
20. Bolus fluorouracil induced syncope and pulseless ventricular tachycardia: a case report.
Fidan E; Fidan S; Yildiz B; Durmus I; Kavgaci H; Ozdemir F; Aydin F
Hippokratia; 2011 Jan; 15(1):93-5. PubMed ID: 21607046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
